Medium
About Respiratory Illness Vaccines
Medium
h2
Left
About Respiratory Illness Vaccines
- Options: A vaccine that targets 3 strains of flu, updated annually
- Eligibility: Ages 6 months+
- Effectiveness: Reduces risk of hospitalization and health care visits by 40-60%
- When to get: Available throughout flu season; ideal to get by end of October
- Options: Updated as needed to match dominant strain (Pfizer mRNA, Moderna mRNA, Novavax)
- Eligibility: Ages 6 months+
- Effectiveness: Reduces risk of severe illness by 40-60%
- When to get: Available any time, discuss timing with your provider
- Options: GSK, Pfizer, Moderna (mRNA)
- Eligibility: Ages 75 years+ and ages 60-74 years at high risk
- Effectiveness: Reduces risk of severe illness by 82-86%
- When to get: Anytime (summer or fall may be best), discuss with your provider
- Options: Pfizer
- Eligibility: Pregnant people who have not received a dose during a previous pregnancy (protection will pass to baby for first 6 months of life)
- Effectiveness: Reduces risk of severe illness in first 3 months of life by 82%
- When to get: September-January, during 32-36 weeks gestation
- Options: Nirsevimab (Sanofi)
- Eligibility:
- Infants born during RSV season within first 7 days of life
- Infants ages <8 months entering their first RSV season
- Children ages 8-19 months entering second RSV season at higher risk, including all American Indian children
- Effectiveness: 98% effective against hospitalization during the 2023-2024 RSV season
- When to get: October - March
Medium
Medium
Medium
Medium